Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tiragolumab + atezolizumab versus placebo + atezolizumab after resection and adjuvant chemotherapy in PD-L1-positive NSCLC
ChiCTR2400081195Phase 3Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab and atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: disease-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400081195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081195.